How can we assess quality of life in AML patients?
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL
The Myeloma 2016 meeting: Integrating science and clinical practice
The significance of FLT3 mutations in AML
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?